WASHINGTON, D.C. - A District of Columbia federal judge did not err in granting the Food and Drug Administration summary judgment on allegations the agency improperly denied the makers of the brand name drug Seroquel an extended period of exclusivity, the District of Columbia U.S. Circuit Court of Appeals ruled April 26 (AstraZeneca Pharmaceuticals LP v. Food and Drug Administration, No. 12-5227, D.C. Cir.).